comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 00:07:15 - browse：4328

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： BIO selects John Crowley as new CEO

focus

WSS

How clinical AI models' predictive power can degrade over time

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Researchers CRISPR chickens in bid to protect them from bird flu

What don’t we know about an Alzheimer’s drug side effect?

Takeda, Janssen join wearable maker to measure scratching

What the Wegovy shortage looks like for doctors — and for patients

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

What's changing in Medicare's open enrollment this year?

Activists slam private health insurers over coverage restrictions

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

FDA approval of Sarepta Duchenne genetic therapy gives me hope

J&J to emphasize cancer drugs, stop much of its vaccine research

United colonoscopy coverage change 'may cost lives,' doctors say

Rep. Raul Ruiz on the physician shortage and more

After affirmative action ruling, medical educators look to 'holistic review'

Bernie Sanders bashes nonprofit hospitals over their tax breaks

hotspot

What the Wegovy shortage looks like for doctors — and for patients

What's changing in Medicare's open enrollment this year?

Wellcome Trust names Røttingen as its new CEO

Takeda, Janssen join wearable maker to measure scratching

Pediatric cancer treatments threatened by a new FDA policy

Fetal surgery at risk from Dobbs and new abortion restrictions

Wikipedia

hotspot

focus

focus